Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease

Objective This study was performed to clarify the influence of nonalcoholic fatty liver disease (NAFLD) on liver stiffness measurement (LSM) and establish a new diagnostic model. Methods A retrospective cohort of 601 patients with chronic hepatitis B (CHB) was enrolled as the derivation group, and a...

Full description

Bibliographic Details
Main Authors: Nan Xu, Qinxiu Xie, Jiang Li, Yufeng Gao, Xu Li
Format: Article
Language:English
Published: SAGE Publishing 2020-02-01
Series:Journal of International Medical Research
Online Access:https://doi.org/10.1177/0300060520903667
_version_ 1818402595830497280
author Nan Xu
Qinxiu Xie
Jiang Li
Yufeng Gao
Xu Li
author_facet Nan Xu
Qinxiu Xie
Jiang Li
Yufeng Gao
Xu Li
author_sort Nan Xu
collection DOAJ
description Objective This study was performed to clarify the influence of nonalcoholic fatty liver disease (NAFLD) on liver stiffness measurement (LSM) and establish a new diagnostic model. Methods A retrospective cohort of 601 patients with chronic hepatitis B (CHB) was enrolled as the derivation group, and a prospective cohort of 30 patients with concurrent CHB and NAFLD was enrolled as the validation group. Results The area under the receiver operating characteristic curve of LSM in patients with CHB without NAFLD (0.792) was higher than that in patients with concurrent CHB and NAFLD (0.720) in diagnosing significant liver fibrosis. Patients with concurrent CHB and NAFLD had significantly higher LSM values than those without NAFLD among the overall F0-F1 patients (6.88 vs. 5.80). The LSM value in the higher controlled attenuation parameter (CAP) quartile was significantly higher than that in the normal CAP quartile among F0-F1 patients (6.80 vs. 5.74). The efficacy of our new diagnostic model for liver fibrosis (Fibro-NAFLD) was higher than that of LSM in both study groups. Conclusion NAFLD with a high CAP value increases the risk of false-positive diagnosis of significant fibrosis. The Fibro-NAFLD model improves the diagnostic efficacy of LSM in patients with concurrent CHB and NAFLD.
first_indexed 2024-12-14T08:10:52Z
format Article
id doaj.art-76f69b4959af444aa9bb82945b4017ce
institution Directory Open Access Journal
issn 1473-2300
language English
last_indexed 2024-12-14T08:10:52Z
publishDate 2020-02-01
publisher SAGE Publishing
record_format Article
series Journal of International Medical Research
spelling doaj.art-76f69b4959af444aa9bb82945b4017ce2022-12-21T23:10:04ZengSAGE PublishingJournal of International Medical Research1473-23002020-02-014810.1177/0300060520903667Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver diseaseNan Xu0Qinxiu Xie1Jiang Li2Yufeng Gao3Xu Li4 Department of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, China Department of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, China Department of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, China Department of Liver and Infectious Diseases, the Second Affiliated Hospital of Anhui Medical University, Hefei, China Department of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, ChinaObjective This study was performed to clarify the influence of nonalcoholic fatty liver disease (NAFLD) on liver stiffness measurement (LSM) and establish a new diagnostic model. Methods A retrospective cohort of 601 patients with chronic hepatitis B (CHB) was enrolled as the derivation group, and a prospective cohort of 30 patients with concurrent CHB and NAFLD was enrolled as the validation group. Results The area under the receiver operating characteristic curve of LSM in patients with CHB without NAFLD (0.792) was higher than that in patients with concurrent CHB and NAFLD (0.720) in diagnosing significant liver fibrosis. Patients with concurrent CHB and NAFLD had significantly higher LSM values than those without NAFLD among the overall F0-F1 patients (6.88 vs. 5.80). The LSM value in the higher controlled attenuation parameter (CAP) quartile was significantly higher than that in the normal CAP quartile among F0-F1 patients (6.80 vs. 5.74). The efficacy of our new diagnostic model for liver fibrosis (Fibro-NAFLD) was higher than that of LSM in both study groups. Conclusion NAFLD with a high CAP value increases the risk of false-positive diagnosis of significant fibrosis. The Fibro-NAFLD model improves the diagnostic efficacy of LSM in patients with concurrent CHB and NAFLD.https://doi.org/10.1177/0300060520903667
spellingShingle Nan Xu
Qinxiu Xie
Jiang Li
Yufeng Gao
Xu Li
Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
Journal of International Medical Research
title Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
title_full Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
title_fullStr Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
title_full_unstemmed Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
title_short Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
title_sort improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis b and nonalcoholic fatty liver disease
url https://doi.org/10.1177/0300060520903667
work_keys_str_mv AT nanxu improvementinliverstiffnessmeasurementfordiagnosisofliverfibrosisinpatientswithconcurrentchronichepatitisbandnonalcoholicfattyliverdisease
AT qinxiuxie improvementinliverstiffnessmeasurementfordiagnosisofliverfibrosisinpatientswithconcurrentchronichepatitisbandnonalcoholicfattyliverdisease
AT jiangli improvementinliverstiffnessmeasurementfordiagnosisofliverfibrosisinpatientswithconcurrentchronichepatitisbandnonalcoholicfattyliverdisease
AT yufenggao improvementinliverstiffnessmeasurementfordiagnosisofliverfibrosisinpatientswithconcurrentchronichepatitisbandnonalcoholicfattyliverdisease
AT xuli improvementinliverstiffnessmeasurementfordiagnosisofliverfibrosisinpatientswithconcurrentchronichepatitisbandnonalcoholicfattyliverdisease